ES
MARKETS / NASDAQ / BBNX
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Beta Bionics, Inc. BBNX

3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$100.3M
▲ 53.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-346.5%
Net margin · FY25
-73.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 100.3M
Revenue, FY2025 · full 3-year series below
Revenue Net income
0.040.080.120.1-0.120232025
0.040.080.120.1-0.120232025

The company lost 73 cents on every revenue dollar this year.

Per share
—
Diluted EPS, FY2025
EPS
0.40.81.220232025
0.40.81.220232025

The company pays no cash dividend.

Profitability
-346.5%
Return on equity, FY2025
ROE
0.250.50.751-346.5%20232025
0.250.50.751-346.5%20232025
Operating margin-71.5%
Net margin-73.0%
Return on assets-30.6%

Each USD of equity lost 347 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 328.7M
total assets, end of FY2025
Total assetsUSD 328.7M
EquityUSD 287.6M
CashUSD 31.6M
Current ratio8.66×

Equity funds 87% of total assets.

History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.1
0.1
0.0
Operating income $B
−0.1
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
·
Net income $B
−0.1
−0.1
−0.0
EPS, diluted $
·
·
·
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−346.5
·
·
Shares out B
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
12 of 12
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed